Company: ANTX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001193125-25-277673
Chunk: 11

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 6
Chunk 11
---
, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

     101.INS
      
     Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document.

     101.SCH
      
     Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Document**

     104
      
     Cover Page Interactive Data File (embedded within the Inline XBRL document)

* Filed herewith.

** The following materials are formatted in Inline XBRL (Extensible Business Reporting Language): (i) the cover page; (ii) the Condensed Balance Sheets as of September 30, 2025 and December 31, 2024; (iii) the Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2025 and 2024; (iv) the Condensed Statements of Stockholders' Equity for the three and nine months ended September 30, 2025 and 2024; (vi) the Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024; (vii) Notes to Unaudited Condensed Financial Statements tagged as blocks of text.

† The certification attached as Exhibit 32.1 and Exhibit 32.2 that accompany this Quarterly Report on Form 10-Q is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Quarterly Report on Form 10-Q, irrespective of any general incorporation language contained in such filing.